澳大利亚孕产妇呼吸道合胞病毒(RSV)疫苗接种的成本效果估算:动态与经济模型分析
研究运用动态与经济评价整合模型,估算澳大利亚全年孕产妇RSV疫苗接种项目的成本效果。医疗系统视角下,疫苗价格低于约120澳元时具成本效果(支付意愿阈值50,000澳元/QALY)。82%的成本节约来自预防<6月龄婴儿住院,但仅约25%的QALY增益在该年龄组;排除≥6月龄的成本节约与QALY增益后,满足阈值的疫苗价格降至63澳元。
要点
- 全年孕产妇RSV疫苗接种项目在疫苗价格低于约120澳元时具成本效果。
- 82%成本节约来自预防<6月龄婴儿RSV住院,但该年龄组仅占约25%的QALY增益。
- 多数其他QALY增益来自 herd effects(群体效应),即预防老年人死亡及减少较大青少年和成人非就医疾病。
核心结论
- 澳大利亚孕产妇RSV疫苗接种项目可通过减少<6月龄婴儿住院及相关费用提供经济价值,具体取决于疫苗价格。
- 目标人群之外的 herd effects(群体效应)可能是评估孕产妇RSV疫苗接种成本效果的重要考虑因素。
研究设计与样本
- 研究应用整合动态与经济评价模型,估算澳大利亚全年孕产妇RSV疫苗接种项目的特定结局与成本效果。
- 成本效果以每获得一个质量调整生命年(QALY)的增量成本效果比(ICER)估算。
主要发现
- 医疗系统视角下,假设支付意愿阈值为50,000澳元/QALY,疫苗价格低于约120澳元时项目具成本效果。
- 82%的成本节约来自预防<6月龄婴儿RSV住院,但仅约25%的QALY增益在该年龄组。
- 多数其他QALY增益来自 herd effects(群体效应),即预防老年人死亡,以及较小程度来自预防较大青少年和成人非就医疾病。
- 排除≥6月龄的成本节约与QALY增益后,满足假设支付意愿阈值所需疫苗价格降至63澳元。
关键数值与推荐
- 支付意愿阈值假设为50,000澳元/QALY。
- 医疗系统视角下,疫苗价格低于约120澳元时项目具成本效果。
- 排除≥6月龄的成本节约与QALY增益后,满足支付意愿阈值所需疫苗价格降至63澳元。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Respiratory syncytial virus (RSV) is a major cause of respiratory illness, with younger infants at greatest risk of hospitalisation. With the recent approval of a maternal RSV vaccine in Australia, it is timely to evaluate its potential costs and health benefits in Australia. METHODS: We applied an integrated dynamic and economic evaluation model to estimate specific outcomes of RSV disease and the cost-effectiveness of a year-round maternal RSV vaccination program in Australia. Cost-effectiveness was estimated using the incremental cost-effectiveness ratio (ICER) per quality-adjusted life year (QALY) gained. RESULTS: From a healthcare system perspective, the maternal vaccination program was estimated to be cost-effective at a vaccine price less than approximately 120 Australian dollars ($AU), assuming a willingness-to-pay (WTP) threshold of $AU 50,000/QALY gained. Most of the estimated cost-savings were from preventing RSV hospitalisations in infants aged <6 months. However, while 82% of the cost-savings were from preventing RSV hospitalisations in infants aged <6 months, only about 25% of the QALY gains were in this age group. The majority of the other QALY gains came via herd effects from prevention of death in older adults and to a lesser extent, prevention of nonmedically-attended illness in older teens and adults. When predicted cost-savings and QALY gains in those ≥6 months of age were excluded, the vaccine price required to meet the assumed WTP threshold fell to $AU 63. CONCLUSIONS: A maternal RSV vaccination program in Australia could provide value for money by reducing hospitalisations and associated costs among infants aged <6 months, depending on the vaccine price. We have provided evidence that herd effects beyond the target population may be an important consideration in assessing cost-effectiveness of maternal RSV vaccination.
引用
- Nazareno AL, Wood JG, Muscatello DJ, et al. Estimating the cost-effectiveness of maternal respiratory syncytial virus (RSV) vaccination in Australia: A dynamic and economic modelling analysis. Vaccine. 2024. PMID: 39733477. doi:10.1016/j.vaccine.2024.126651
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。